The Novartis Access portfolio includes 15 on- and off-patent medicines addressing against cardiovascular diseases, type 2 diabetes, breast cancer and respiratory illnesses. These diseases together are responsible for 82% of all NCD deaths.
It is offered as a basket to governments, NGOs and other public-sector customers in low and lower middle income countries at a price of USD 1 per treatment per month.
Beyond the portfolio, Novartis Access offers capacity-building activities to support healthcare system in preventing, diagnosing and treating NCDs.
Tracking our progress
We are aiming to roll out Novartis Access in 30 countries in the coming years, depending on government and stakeholder demand – hoping to reach 20 million patients per year by 2020.
The burden of noncommunicable diseases (NCDs) like cardiovascular diseases, diabetes and cancer in the developing world is increasing. These conditions disproportionally affect poverty-stricken areas. Already today 28 million people die each year from these types of diseases in low- and middle-income countries – representing nearly 75% of deaths from NCDs globally. Combined with the existing challenge of managing infectious diseases, these countries are now confronted by a double disease burden. Because chronic illnesses require early detection and long-term, ongoing treatment, we need new ways to ensure access to affordable medicines for NCDs in countries where people often have limited resources.
The Novartis Access one-year report describes first results, early learnings and challenges from our first twelve months on the ground. It also includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.